GlassScriptPhysician profile
Nancy C Brownlee
NPI 1962827451
$3,513.10
in general payments reported to CMS, 2019-2025
27 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $799 · 2022: $203 · 2023: $706 · 2024: $621 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,510.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $623.44 | 2021-2025 | Epclusa, Livdelzi, Vemlidy |
| Abbvie INC. | $287.10 | 2021-2025 | |
| Novo Nordisk INC | $221.30 | 2021-2023 | |
| Inspire Medical Systems, INC. | $219.96 | 2024-2025 | Inspire |
| Genzyme Corporation | $196.60 | 2021-2024 | |
| Madrigal Pharmaceuticals | $139.99 | 2025 | Rezdiffra |
| Abbott Laboratories | $136.58 | 2025 | Proclaim |
| Silk Road Medical, INC. | $133.74 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Coloplast Corp | $133.31 | 2023-2024 | Altis, Titan |
| Csl Behring | $124.64 | 2024 | Hizentra |
| Alexion Pharmaceuticals, INC. | $123.66 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $121.86 | 2025 | Saphnelo |
| Acadia Pharmaceuticals INC | $120.99 | 2024 | Daybue |
| Corcept Therapeutics | $113.35 | 2025 | Korlym |
| Axsome Therapeutics, INC. | $97.61 | 2025 | Auvelity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $93.62 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $87.51 | 2021 | |
| Mylan Specialty L.P. | $85.09 | 2023 | Yupelri |
| Abiomed | $82.00 | 2025 | |
| Jazz Pharmaceuticals INC. | $77.88 | 2025 | |
| Stemline Therapeutics INC. | $77.88 | 2022 | |
| Astellas Pharma US INC | $56.75 | 2021 | |
| Laborie Medical Technologies Corp. | $51.90 | 2021-2022 | |
| Pfizer INC. | $40.27 | 2023 | |
| 180 Medical, INC. | $28.30 | 2021 | |
| Healthtronics Stone Solutions, LLC | $20.00 | 2021 | |
| Myovant Sciences INC. | $17.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Brownlee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.